Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs). It exhibits anticancer activity and is used in the treatment of small cell lung cancer (SCLC).
Purity:
95.00%
CAS Number:
[1613313-01-1]
Target:
Gamma-secretase
* VAT and and shipping costs not included. Errors and price changes excepted